Impact of disease management programs on women with breast cancer in Germany

Breast Cancer Research and Treatment

Volumn 153, Issue 2, 2015, Pages 391-395

  Jacob, Louis ^a   Hadji, Peyman ^b   Albert, Ute Susann ^b   Kalder, Matthias ^c   Kostev, Karel ^d  

^a UNIVERSITÉ DE LYON   (France)

^b Nord West Hospital   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d IQVIA   (United States)

Author keywords

Breast cancer; Compliance; Disease management program

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CHRONIC DISEASE; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; FEMALE; GERMANY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOSIS; AGED; BREAST NEOPLASMS; COMORBIDITY; DISEASE MANAGEMENT; FACTUAL DATABASE; HEALTH CARE QUALITY; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMORBIDITY; DATABASES, FACTUAL; DISEASE MANAGEMENT; FEMALE; GERMANY; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STANDARD OF CARE;

EID: 84940961763     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3530-0     Document Type: Article

References (29)

1. World Cancer Research Fund International: Breast cancer statistics (2015). Accessed 13 July 2015
2. Gemmill M: Research note: Chronic Disease Management in Europe—European Commission [Internet]
3. Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S (1997) Evidence-based disease management. JAMA 278:1687–1692
4. Rupprecht C (2005) First German disease management program for breast cancer. Health Care Financ Rev 27:69–77
5. World Health Organization: Adherence to long-term therapies: evidence for action [Internet]. 2003
6. Sackett DL, Haynes RB, Gibson ES, Taylor DW, Roberts RS, Johnson AL (1978) Patient compliance with antihypertensive regimens. Patient Couns Health Educ 1:18–21
7. Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R (2000) Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. doi:10.1002/14651858.CD000011
8. Balkrishnan R (2005) The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 43:517–520
9. Davidson B, Vogel V, Wickerham L (2007) Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. J Support Oncol 5:139–143
10. Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt N, Kostev K (2013) Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 138:185–191. doi:10.1007/s10549-013-2417-1
11. Becher H, Kostev K, Schröder-Bernhardi D (2009) Validity and representativeness of the “disease analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47:617–626
12. Masood S (1992) Estrogen and progesterone receptors in cytology: a comprehensive review. Diagn Cytopathol 8:475–491
13. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol Off J Am Soc Clin Oncol 32:2255–2269. doi:10.1200/JCO.2013.54.2258
14. Matsen CB, Neumayer LA (2013) Breast cancer: a review for the general surgeon. JAMA Surg 148:971–979. doi:10.1001/jamasurg.2013.3393
15. O’Malley BW, Khan S (2013) Elwood V. Jensen (1920–2012): father of the nuclear receptors. Proc Natl Acad Sci U. S. A. 110:3707–3708. doi:10.1073/pnas.1301566110
16. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet Lond Engl 351:1451–1467
17. Jordan VC (2008) Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer Oxf Engl 44:30–38. doi:10.1016/j.ejca.2007.11.002
18. Mourits MJE, De Vries EGE, Willemse PHB, Ten Hoor KA, Hollema H, Van der Zee AGJ (2001) Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 97:855–866. doi:10.1016/S0029-7844(00)01196-0
19. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88:832–834
20. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537
21. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrère CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet Lond Engl 343:448–452
22. Sasco AJ, Chaplain G, Amoros E, Saez S (1996) Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiol Camb Mass 7:9–13
23. Partridge AH, Avorn J, Wang PS, Winer EP (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94:652–661
24. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690
25. Altundag K, Ibrahim NK (2006) Aromatase inhibitors in breast cancer: an overview. Oncologist 11:553–562. doi:10.1634/theoncologist.11-6-553
26. Evans CT, Ledesma DB, Schulz TZ, Simpson ER, Mendelson CR (1986) Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. Proc Natl Acad Sci U S. A 83:6387–6391
27. Nelson LR, Bulun SE (2001) Estrogen production and action. J Am Acad Dermatol 45:S116–S124
28. Buzdar AU, Coombes RC, Goss PE, Winer EP (2008) Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112:700–709. doi:10.1002/cncr.23193
29. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A (2005) Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 330:702. doi:10.1136/bmj.38343.670868.D3